Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | SIK1 | P57059 | 1/20 | 0.40 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535579 | 1.00 | LYN (0.46) | LYNBTKPSEN1PSEN2APH1B | |
| SCHEMBL4090927 | 0.83 | RIPK2 (0.46) | LYNBTKPSEN1PSEN2APH1B | |
| SCHEMBL29535927 | 0.82 | FGFR1 (0.50) | LYNBTKPSEN1PSEN2APH1B | |
| SCHEMBL22719021 | 0.82 | FGFR1 (0.50) | LYNBTKPSEN1PSEN2APH1B | |
| SCHEMBL29498200 | 0.81 | LCK (0.56) | LYNBTKPSEN1PSEN2APH1B | |
| SCHEMBL4181352 | 0.81 | LCK (0.56) | LYNBTKPSEN1PSEN2APH1B | |
| SCHEMBL22719107 | 0.79 | SRC (0.41) | LYNBTKSRCTP53CYP1A2 | |
| SCHEMBL5114845 | 0.77 | MAPK14 (0.44) | MAPK14CYP1A2HSD17B10USP2CYP2D6 | |
| SCHEMBL20564704 | 0.76 | RIPK2 (0.55) | LYNBTKPSEN1PSEN2APH1B | |
| SCHEMBL29498199 | 0.76 | RIPK2 (0.55) | LYNBTKPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251081-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-08-11 | — | — | US | claimed |
| WO-2020243376-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-12-03 | — | — | WO | claimed |
| US-20220251081-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-08-11 | — | — | US | disclosed |
| WO-2020243376-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251081-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | LYN 4356/4885BTK 4174/4885PSEN1 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.